Work

p16, COX-2, and Ki67 Protein Expression in DCIS and Risk of Ipsilateral Invasive Breast Cancer

Year: 2025

Type: article

Abstract: BACKGROUND: Prior research on the associations of p16, COX-2, and Ki67 immunopositivity in ductal carcinoma in situ (DCIS) tissue with the risk of subsequent ipsilateral invasive breast cancer (IBC) is limited. METHODS: In a case-control study nested in a cohort of women diagnosed with DCIS, immunostaining for p16, COX-2, and Ki67 was performed on DCIS tissue from those who developed subsequent ipsilateral IBC (cases; n = 146) and on matched subjects who did not develop IBC (controls; n = 273). Conditional logistic regression was used to estimate ORs and 95% confidence intervals for the associations between immunopositivity for p16, COX-2, and Ki67 and the risk of subsequent ipsilateral IBC. RESULTS: There was no association between p16, COX-2, and Ki67 immunopositivity, examined either individually or in combination, and a risk of ipsilateral IBC. Compared with all other groups, the multivariable OR (95% confidence interval) for women who were triple positive for the three markers was 1.16 (0.38-3.54). CONCLUSIONS: p16, COX-2, and Ki67 immunopositivity was not associated with altered risk of ipsilateral IBC in women with DCIS. IMPACT: p16, COX-2, and Ki67 may not be prognostic for ipsilateral IBC in women with DCIS.

Source: Cancer Epidemiology Biomarkers & Prevention

DOI: 10.1158/1055-9965.epi-25-0143